Add like
Add dislike
Add to saved papers

Preoperative MTV 2.5 Associated with Early Systemic Metastasis in Resected Pancreatic Cancer: A Transcriptome-Wide Analysis.

Gut and Liver 2018 December 25
Background/Aims: 18 F-fluorodeoxyglucose-positron emission tomography (18 F-FDG-PET) reflects biological aggressiveness and predicts prognoses in various tumors. Evaluating the oncologic significance of the preoperative metabolic phenotype might be necessary for planning the surgical strategy in resectable pancreatic cancer.

Methods: From January 2010 to December 2015, a total of 93 patients with pathologic T3 (pT3) pancreatic cancer were included in this study. Clinicopathological parameters, PET parameters, and transcriptome-wide analysis were performed to identify the oncologic impacts and molecular landscape of the metabolic phenotype of resectable pancreatic cancer.

Results: Preoperative MTV2.5 was significantly higher in the pN1 group (6.5±7.8 vs 11.1±11.2, p=0.031). Higher MTV2.5 values (MTV2.5 ≥4.5) were associated with multiple lymph node metastasis (p=0.003), and the lymph node ratio was also significantly higher in resected pT3 pancreatic cancer with MTV2.5 ≥4.5 (0.05±0.08 vs 0.12±0.13, p=0.001). Disease-specific survival of patients with MTV2.5 <4.5 was better than that of patients with MTV2.5 ≥4.5 (mean, 28.8 months; 95% confidence interval [CI], 40.1 to 57.0 vs mean, 32.6 months; 95% CI, 25.5 to 39.7; p=0.026). The group of patients with MTV2.5 ≥4.5 followed by postoperative adjuvant chemotherapy showed better survival outcomes than patients with MTV2.5 ≥4.5 without adjuvant treatment in resected pT3 pancreatic cancer (p<0.001). Transcriptome-wide analysis revealed that tumors with MTV2.5 ≥4.5 demonstrated significantly different expression of cancer-related genes affecting aggressive tumor biology.

Conclusions: Resectable pancreatic cancer with high MTV2.5 is not only associated with lymph node metastasis but also predicts early systemic metastasis. The molecular background of resectable pancreatic cancer with high MTV2.5 may be associated with aggressive biologic behavior, which might need to be considered when managing resectable pancreatic cancer. Further study is mandatory.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app